Pharma BD Deal Intelligence
A $2.9B all-stock acquisition that gave Novartis full control of MorphoSys's oncology and immunology antibody pipeline. The deal added scale to Novartis's hematology franchise, though the modest premium reflected MorphoSys's thin late-stage pipeline beyond its lead assets.
Novartis acquired MorphoSys for ~$2.9B for oncology and immunology antibodies.
Tulmimetostat (CPI-0209) is a dual EZH2/EZH1 inhibitor targeting ARID1A-mutant ovarian/endometrial, BAP1-loss mesothelioma, and epigenetic-dependent solid tumors. EZH2 inhibitors (direct MOA): Epizyme/Ipsen's Tazverik (tazemetostat) is the approved EZH2-selective inhibitor for epithelioid sarcoma and EZH2-mutant follicular lymphoma, with Ipsen 2024 sales approximately EUR 100M, limited by narrow indications and modest efficacy; Constellation/MorphoSys's tulmimetostat (CPI-0209) is the dual EZH2/EZH1 differentiator in Phase 2; Incyte's INCB59872/ezharmostat is the next-generation competitor. PRC2/EED inhibitors (adjacent MOA): MAK683 (Novartis, discontinued), ORIC/ORIC-944 (PRC2, prostate Phase 1). DNA methyltransferase inhibitors (epigenetic class): Otsuka's Inqovi (decitabine/cedazuridine) and BMS's Vidaza (azacitidine) — primarily hematologic but establish epigenetic-therapy precedent. HDAC inhibitors (broader epigenetic): Celgene/BMS's Istodax (romidepsin) and Merck's Zolinza (vorinostat) are historical. PARP inhibitors (in ARID1A-mutant overlap): Lynparza (olaparib) and Zejula (niraparib) are competing biomarker-driven options in ovarian. Immune checkpoint inhibitors: Keytruda (pembrolizumab) serves as the SOC comparator across solid tumors with MSI-H/TMB biomarkers. For a commercial lead, tulmimetostat's franchise case depends on dual EZH1/EZH2 inhibition delivering activity where Tazverik underperformed (ARID1A loss, BAP1 loss, CTCL), but Tazverik's modest commercial trajectory suggests category economics are limited absent a breakthrough biomarker.
Monjuvi (tafasitamab) in 2L+ DLBCL competes in a fragmented R/R DLBCL landscape reshaped by CAR-T and bispecifics. Anti-CD19 mAbs (direct MOA): Incyte/MorphoSys's Monjuvi (tafasitamab) + Revlimid (lenalidomide) is FDA-approved for 2L+ R/R DLBCL ineligible for ASCT, generating approximately $140M 2024 net sales (Incyte post-divestiture); Novartis acquired through MorphoSys and subsequently divested US rights to Incyte 2024. CAR-T (anti-CD19 cell therapy): Gilead/Kite's Yescarta (axicabtagene ciloleucel, approximately $1.6B 2024 global), BMS's Breyanzi (lisocabtagene maraleucel, $747M 2024), and Novartis's Kymriah (tisagenlecleucel, approximately $400M) dominate 2L/3L DLBCL post ZUMA-7 and TRANSFORM moved Yescarta/Breyanzi to 2L. Anti-CD20 x CD3 bispecifics (rising class): Roche's Columvi (glofitamab, 3L+ DLBCL, approximately CHF 300M 2024) and Lunsumio (mosunetuzumab, FL); AbbVie/Genmab's Epkinly (epcoritamab, 3L+ DLBCL, approximately $300M 2024). Anti-CD79b ADC: Roche's Polivy (polatuzumab vedotin, 1L POLARIX + R-CHP, approximately CHF 1.7B 2024). XPO1 inhibitor: Karyopharm's Xpovio (selinexor). For a commercial lead, Monjuvi's divestiture reflects its difficult position — squeezed between CAR-T (2L SOC in fit patients) and bispecifics (3L+ convenient off-the-shelf), its frail-patient/Revlimid-combo niche is narrow and price-pressured.
Pelabresib enters a myelofibrosis market where JAK inhibitors are entrenched and novel add-on combos compete to improve spleen volume reduction (SVR), anemia, and symptom scores. BET inhibitors (pelabresib's direct MOA): MorphoSys/Novartis's pelabresib (CPI-0610) + ruxolitinib failed to meet statistical significance on symptom endpoint in MANIFEST-2 Phase 3 (2023-24 readout), triggering MorphoSys acquisition/divestiture dynamics; no other BET inhibitor at equivalent MF stage. JAK inhibitors (incumbent SOC): Incyte/Novartis's Jakafi/Jakavi (ruxolitinib, ~$2.7B US Incyte 2024 + Novartis ex-US), BMS's Inrebic (fedratinib), GSK's Ojjaara (momelotinib, anemia-differentiated JAKi, approved 2023, ramping 2024), and Incyte/CTI's Vonjo (pacritinib, cytopenic MF) define the class. BCL-XL inhibitors (combo class): AbbVie's navitoclax (Phase 3 TRANSFORM-1 + ruxolitinib, mixed 2024 readout with dose-dependent thrombocytopenia). MDM2 inhibitors (combo class): Kartos/Telios's navtemadlin (KRT-232, Phase 3 BOREAS 2L MF, 2025 data). PI3K-delta inhibitors: parsaclisib (development halted). Anemia agents: BMS's Reblozyl (luspatercept) for transfusion-dependent MPNs. For a commercial lead, pelabresib's path forward post-MANIFEST-2 is narrow — the clearest combo differentiation failed and Ojjaara's anemia benefit plus momelotinib's expanding label make the MF 1L combo race increasingly about cytopenia-friendly JAKi partners, not BET.
Novartis completed ~$2.9B acquisition of MorphoSys, gaining Monjuvi (tafasitamab) for DLBCL and HuCAL antibody discovery platform.
Pelabresib (from MorphoSys) advancing through Phase 3 in myelofibrosis, potentially the most valuable asset alongside the antibody platform.
Monjuvi modest commercially but pelabresib in myelofibrosis could be significant. HuCAL platform provides R&D value. Verdict depends on pelabresib approval.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Novartis AG / MorphoSys AG (this deal) | 2024 | $2.9B | 36 |
| Novartis AG / Advanced Accelerator Applications S.A. | 2017 | $3.9B | 98 |
| Novartis AG / Endocyte, Inc. | 2018 | $2.1B | 96 |
| Novartis AG / Lek Pharmaceuticals d.d. | 2002 | $876M | 88 |
| Novartis AG / GlaxoSmithKline plc | 2014 | $16.0B | 81 |
| Novartis AG / PTC Therapeutics Inc. | 2024 | $2.9B | 80 |
| Novartis AG / Chinook Therapeutics Inc. | 2023 | $3.5B | 78 |
← Browse all deals · How we score deals
More: 2024 deals · Novartis AG deals · Oncology deals